Novo Nordisk

News

FDA finds no link between GLP-1 drugs and suicide

The FDA has given an update on its ongoing review of a possible link between GLP-1 agonist drugs used to treat diabetes and obesity and suicide, saying it can find no evid

News

Novo Nordisk’s Flagship alliance bears obesity, MASH fruit

Novo Nordisk has reaped the first harvest from its wide-ranging alliance with life sciences investor Flagship Pioneering, buying rights to two programmes from the VC’s por

News

Novo Nordisk will open AI hub in London

Novo Nordisk is planning to open an artificial intelligence (AI) research facility in London, UK, as part of a drive to place the technology at the heart of its drug disco

News

Novo Nordisk will invest €2.1bn in French manufacturing site

Novo Nordisk has made another major capital investment in production capacity for its diabetes and obesity therapies, agreeing to spend €2.1 billion ($2.3 billion) on a fa

Market Access

Health Innovators – Aleks Engel

One month ago, editor-in-chief Jonah Comstock travelled to Copenhagen, Denmark to visit the Novo Nordisk Foundation.

News

AHA: Wegovy improves survival in outcomes trial

Novo Nordisk’s obesity therapy Wegovy has cut the risk of death by 19% in the SELECT trial, mirroring the benefits of the drug in cardiovascular outcomes in people who are

FDA finds no link between GLP-1 drugs and suicide

Novo Nordisk’s Flagship alliance bears obesity, MASH fruit

Novo Nordisk will open AI hub in London

Novo Nordisk will invest €2.1bn in French manufacturing site

Health Innovators – Aleks Engel

AHA: Wegovy improves survival in outcomes trial

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Novo Nordisk

Editor's Picks